Conclusion It is evident that TCRVα24~+ NKT cells and CD3~+CD56~+CIK cells differ absolutely in many ways and might play different roles in anti-tumor immunity and immune regulation.
An Elementary Study on the Mechanisms of Vα24NKT Cells from Human Peripheral Blood Cells in Anti-tumor Immunity and a Comparative Study on the Biological Characteristics of Vα24NKT Cells and CD3~+CD56~+CIK Cells
Otherwise,the increasing of CD3+CD8+ T cells in the CTL induced by DC pulsed with U937 frozen-thawed antigen suggests the main role of the CD3+CD8+ T cells in the anti-tumor immunity.
Conclusion : These modified B16/pcDNA_3-Ag85B cells significantly enhanced the proliferation of PBMCs of PPD~+ human donors, which provided foundation to the study of Ag85B antitumor immune activity.
CONCLUSION The hepatocellular immune injury and effective anti-tumor immune response might be induced by sufficient expression of CD54, CD80, CD86 and HLA-ABC concurrently, and absence or poor expression of CD80 and CD86 might be the main reason for immune escape of hepatocarcinoma.
Lung cancer cells can upregulate the expression of Fas ligand (FasL) and counterattack tumor-infiltration lymphocyte (TIL) expressing Fas via the FasL/Fas pathway, therefore escaping from immunosurvillance and impairing local anti-tumor immune capacity.
Molecular identification of tumor-associated antigens not only provided the means to activate or monitor anti-tumor immunity, but also gave insights into new and unexpected biochemical processes that are taking place within cells.
Dendritic cells (DC)-derived or tumor-derived exosomes are a population of nanometer sized membrane vesicles that can induce specific anti-tumor immunity.
Our findings suggest that Exo/IL-18 has more potent capability to induce specific anti-tumor immunity, and our strategy of IL-18 modification of exosomes is a feasible approach to develop exosomes-based tumor vaccines.
This apparent stimulation of anti-tumor immunity was observed in treated animals regardless of substrain or site of MER injection, and could not be correlated with the outcome of immunotherapy.
Expression of interleukin-12 (IL-12) on tumor-cell membranes in a GPI-anchored form induces a strong antitumor immune response that is comparable to the effects of secretory IL-12.
Although there is ample evidence for the presence of tumor-associated antigens on a variety of tumors, they are seemingly unable to elicit an adequate antitumor immune response.
Translation of these preclinical results primarily into melanoma patients with advanced diseases shows the potential to induce systemic antitumor immune responses and in some instances tumor regression with acceptably low toxicity.
The specific anti-tumor immune response induced by mouse bone marrow dendritic cells (DCs) transfected with recombinant adenovirus carrying mutant k-ras genes was investigated.
Decreased immune function in cancer patients is well-characterized (I), and tumor cells have developed a variety of mechanisms, to avoid anti-tumor immune responses (2-8).
In addition, by regulating immunity, chemokines critically regulate anti-tumor immune responses and chronic inflammation such as that associated with various neoplasias.